Isabella Ferreira

TL;DR: The B.617.1.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike as discussed by the authors.

TL;DR: In this paper, the authors report chronic SARS-CoV-2 with reduced sensitivity to neutralizing antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences over 23 time points spanning 101 days.

TL;DR: The SARS-CoV-2 Omicron BA.1 variant emerged in 20211 and has multiple mutations in its spike protein this paper , which increased the evasion of therapeutic monoclonal and vaccine-elicited polyclonal neutralizing antibodies after two doses.

TL;DR: In this article, the authors assessed the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b22.1.7 and found that the emergence of the E484K substitution in a B.1, 1.1., 1.7 background represents a threat to the efficacy of the BNT 162b2 vaccine.

TL;DR: In this article , the SARS-CoV-2 Omicron BA has multiple mutations in its spike protein, which increases evasion of therapeutic monoclonal and vaccine-elicited polyclonal neutralizing antibodies after two doses.